Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more
Shanghai Labway Clinical Laboratory Co Ltd (301060) - Net Assets
Latest net assets as of September 2025: CN¥1.67 Billion CNY
Based on the latest financial reports, Shanghai Labway Clinical Laboratory Co Ltd (301060) has net assets worth CN¥1.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.43 Billion) and total liabilities (CN¥760.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.67 Billion |
| % of Total Assets | 68.72% |
| Annual Growth Rate | 27.04% |
| 5-Year Change | 45.93% |
| 10-Year Change | 496.35% |
| Growth Volatility | 35.61 |
Shanghai Labway Clinical Laboratory Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Shanghai Labway Clinical Laboratory Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Labway Clinical Laboratory Co Ltd (2013–2024)
The table below shows the annual net assets of Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.82 Billion | -8.07% |
| 2023-12-31 | CN¥1.98 Billion | -12.87% |
| 2022-12-31 | CN¥2.27 Billion | +38.60% |
| 2021-12-31 | CN¥1.64 Billion | +31.46% |
| 2020-12-31 | CN¥1.25 Billion | +2.82% |
| 2019-12-31 | CN¥1.21 Billion | +2.71% |
| 2018-12-31 | CN¥1.18 Billion | +6.94% |
| 2017-12-31 | CN¥1.10 Billion | +79.66% |
| 2016-12-31 | CN¥614.70 Million | +101.38% |
| 2015-12-31 | CN¥305.25 Million | +51.76% |
| 2014-12-31 | CN¥201.13 Million | +53.78% |
| 2013-12-31 | CN¥130.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Labway Clinical Laboratory Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 676.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥640.79 Million | 38.65% |
| Common Stock | CN¥400.52 Million | 24.15% |
| Other Comprehensive Income | CN¥-653.31K | -0.04% |
| Other Components | CN¥617.48 Million | 37.24% |
| Total Equity | CN¥1.66 Billion | 100.00% |
Shanghai Labway Clinical Laboratory Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Labway Clinical Laboratory Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wuxi Chemical Equipment Co. Ltd. A
SHE:001332
|
$226.85 Million |
|
7C Solarparken AG
PINK:SCPKF
|
$227.05 Million |
|
Odfjell B
OL:ODFB
|
$227.05 Million |
|
Lumibird SA
PA:LBIRD
|
$227.06 Million |
|
Blue Ridge Bankshares Inc
NYSE MKT:BRBS
|
$226.82 Million |
|
Xinjiang Sayram Modern Agriculture Co Ltd
SHG:600540
|
$226.80 Million |
|
Guangzheng Group Co Ltd
SHE:002524
|
$226.79 Million |
|
IEI Integration Corp
TW:3022
|
$226.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Labway Clinical Laboratory Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,780,316,277 to 1,658,128,422, a change of -122,187,855 (-6.9%).
- Net loss of 109,436,221 reduced equity.
- Dividend payments of 7,356,726 reduced retained earnings.
- Share repurchases of 12,751,633 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-109.44 Million | -6.6% |
| Dividends Paid | CN¥7.36 Million | -0.44% |
| Share Repurchases | CN¥12.75 Million | -0.77% |
| Other Changes | CN¥7.36 Million | +0.44% |
| Total Change | CN¥- | -6.86% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Labway Clinical Laboratory Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 31.79x to 2.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.33 | CN¥10.38 | x |
| 2014-12-31 | CN¥0.50 | CN¥10.38 | x |
| 2015-12-31 | CN¥3.38 | CN¥10.38 | x |
| 2016-12-31 | CN¥6.11 | CN¥10.38 | x |
| 2017-12-31 | CN¥3.06 | CN¥10.38 | x |
| 2018-12-31 | CN¥3.27 | CN¥10.38 | x |
| 2019-12-31 | CN¥2.95 | CN¥10.38 | x |
| 2020-12-31 | CN¥3.05 | CN¥10.38 | x |
| 2021-12-31 | CN¥3.91 | CN¥10.38 | x |
| 2022-12-31 | CN¥5.15 | CN¥10.38 | x |
| 2023-12-31 | CN¥4.40 | CN¥10.38 | x |
| 2024-12-31 | CN¥4.09 | CN¥10.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Labway Clinical Laboratory Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.28%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 1.58x
- Recent ROE (-6.60%) is below the historical average (15.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 64.49% | 18.23% | 1.40x | 2.52x | CN¥71.26 Million |
| 2014 | 34.97% | 13.00% | 1.17x | 2.30x | CN¥50.23 Million |
| 2015 | 27.21% | 13.53% | 1.08x | 1.87x | CN¥52.06 Million |
| 2016 | 10.16% | 7.30% | 0.85x | 1.63x | CN¥898.29K |
| 2017 | 0.60% | 0.70% | 0.69x | 1.23x | CN¥-101.44 Million |
| 2018 | 6.37% | 6.97% | 0.73x | 1.25x | CN¥-41.81 Million |
| 2019 | 7.81% | 8.00% | 0.82x | 1.18x | CN¥-25.83 Million |
| 2020 | 9.03% | 8.91% | 0.84x | 1.20x | CN¥-11.85 Million |
| 2021 | 13.03% | 11.46% | 0.84x | 1.35x | CN¥47.35 Million |
| 2022 | 29.92% | 14.70% | 1.12x | 1.82x | CN¥411.00 Million |
| 2023 | -7.95% | -8.46% | 0.56x | 1.68x | CN¥-319.62 Million |
| 2024 | -6.60% | -6.28% | 0.66x | 1.58x | CN¥-275.25 Million |
Industry Comparison
This section compares Shanghai Labway Clinical Laboratory Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,872,281,787
- Average return on equity (ROE) among peers: 7.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | CN¥1.67 Billion | 64.49% | 0.46x | $226.85 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |